Her-2阳性转移性乳腺癌的生物靶向治疗

目的:回顾性分析本院2010年至2012年Her-2阳性转移性乳腺癌患者的治疗经验，评价在曲妥珠单抗联合紫杉醇治疗的基础上联合与不联合帕妥珠单抗的疗效。方法:设定一定的入选及排除标准，筛选出符合要求的病例进行分析。采用曲妥珠单抗+帕妥珠单抗联合紫杉醇治疗的患者为观察组（54例），曲妥珠单抗+紫杉醇治疗的患者为对照组（71例），比较2种治疗方法的疗效。结果:相比于曲妥珠单抗+紫杉醇，曲妥珠单抗+帕妥珠单抗联合紫杉醇治疗在肿瘤缓解率及肿瘤无进展生存期方面具有明显优势，差异有统计学意义（P＜0.05）。结论:曲妥珠单抗+帕妥珠单抗联合紫杉醇治疗Her-2阳性转移性乳腺癌疗效更好，值得临床推广。

Clinical research of targeted therapy in Her-2 positive metastatic breast cancer

Objective:To evaluate the effect of trastuzumab plus paclitaxel with or without pertuzumab by prospec-tively analyzing the Her-2 positive metastatic breast cancer patients. Methods:The patients were allocated into two groups according to their chemotherapeutic strategy. Patients who treated with trastuzumab and pertuzumab plus pacli-taxel entered the observation group(54 cases)and patients treated with trastuzumab plus paclitaxel without pertuzum-ab entered control group(71 cases). Compare the difference of the effect between the groups. Results:Trastuzumab and pertuzumab plus paclitaxel had a statistical significant better response rate and longer progress free survival than trastuzumab plus paclitaxel(P<0. 05). Conclusion:Trastuzumab and pertuzumab plus paclitaxel is a better choice for Her-2 positive metastatic breast cancer.